BioSpace News Archive

Schrödinger today announced that management will participate in the following conferences in November.

Opening today, the 2023 Milken Institute Future of Health Summit gathers hundreds of speakers and attendees who are inspired to share ideas and advance work around this year’s theme: “Closing the Gap: Better Health for More People.”

Landmark Bio announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) Revive Diagnostics Inc., today announced that it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Eyenovia, Inc. announced that the Company will release financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023, after the markets close.

Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced results for its second fiscal quarter ended September 30, 2023.

Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV-10 (rose bengal sodium) as an adjuvant in vaccines to help them work better was the subject of a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting, which was held in San Diego, CA from November 1-5.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments, previews new Phase 3 MAESTRO study data scheduled for presentation at the AASLD Liver Meeting, and reports third quarter 2023 financial results.

CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL.